PPIDT00355

Drug Information
NameSacituzumab govitecan
SequenceNot Available
DrugBank_IDDB12893
Typebiotech
IndicationSacituzumab govitecan is indicated for adult patients with unresectable locally-advanced or metastatic triple-negative breast cancer (mTNBC) who have undergone two or more prior therapies for metastatic disease by the FDA, Health Canada, and EMA.[L45103,L47596,L47606] It is also indicated for the treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.[L45103,L47596,L47606] These indications are approved in the US, Canada, and Europe. In the US, sacituzumab govitecan is additionally indicated for the treatment of locally advanced or metastatic urothelial cancer in adult patients who have received previous platinum-based therapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This indication has been approved under accelerated approval, and continued approval may be contingent on the demonstration of clinical benefit in confirmatory trials.[L13002]
Dosage Forms
Form Route Strength
Injection, powder, for solution Intravenous
200 mg
Powder, for solution Intravenous
180 mg / vial
Powder, for solution Intravenous
180 mg/1
Solution Intravenous
200.000 mg
Injection Parenteral
200 mg
Injection, powder, lyophilized, for solution Intravenous
20000000 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P09758 TACSTD2 Tumor-associated calcium signal transducer 2 Homo sapiens antibody Link
target P11387 TOP1 DNA topoisomerase 1 Homo sapiens inhibitor Link
target Q96AE4 FUBP1 Far upstream element-binding protein 1 Homo sapiens inhibitor Link
enzyme P22309 UGT1A1 UDP-glucuronosyltransferase 1A1 Homo sapiens substrate Link